Aptamer Therapeutics and Cancer Research UK announce partnership for drug development programme

30th April 2019
Following the successful awarding of a CRUK Biotherapeutic Drug Discovery Project Award, Aptamer Therapeutics Limited, part of Aptamer Group, is pleased to announce a new collaboration with Dan Wiseman and the Oglesby Leukaemia Research Programme at the University of Manchester and Cancer Research UK. The project will explore the potential of aptamers as […]

Aptamer Group March 2019

31st March 2019
This month:

Novel ELISA like assay for small molecules
Moxifloxacin aptamer and intellectual property (IP) availability
Interesting applications in biologic and biosimilar analysis and cell imaging

With lots of exciting new data ongoing for multiple applications in the commercial and academic space, Aptamer Group would like to share with you information that may be […]

  • Working in a lab at Aptamer Group

Aptamer Group January 2019

17th January 2019
This month:

Aptamer Group announces collaboration with AstraZeneca
Cancer Biomarker Capture and Elution by Cell Specific Aptamers
Laboratory and Office expansion
Interesting applications in glioblastoma and hepatocellular carcinoma (HCC) biomarker aptamers

With lots of new data ongoing for multiple applications in the commercial and academic space the Aptamer Group would like to share with […]

Aptamer Group Announces Agreement with AstraZeneca to Explore Next-Generation Drug Delivery Devices

7th January 2019
Aptamer Group today announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney. The two-year agreement will give AstraZeneca use of Aptamer Group’s proprietary technology to explore the feasibility of developing the next generation of drug delivery vehicles, called Aptamer Drug Conjugates (ApDCs).

Aptamers […]

Aptamer Group December 2018

19th December 2018
This month:

Aptamer Group data on selective cell based biomarker aptamers
The year in review, from new product launches to company accolades
Interesting applications in international diagnostics and small molecule lateral flow assays

Novel Solutions – Biomarkers 
Aptamers specific to the same cell type at different stages within a disease cycle

No biomarker abundance restriction
Whole […]

Aptamer Group’s Expansion

14th December 2018

We are proud to announce that we have negotiated an agreement with York Science Park to expand our premises.

The addition of two further laboratories and two offices to our existing space of five labs and four offices will allow us to continue our growth. The additional space has allowed us to set up […]

Aptamer Group November 2018

29th November 2018.
This month:

Aptamer Group data on selective bind and elution reusability of aptamer  purification columns
Small molecule analysis webinar with Pall ForteBio BLI platform
Our CEO Today United Kingdom award
Interesting applications in antibiotic biosensors and ELISA antibody/aptamer pairs

Novel Solutions – Purification 
Reproducibility of aptamers that bind and release under defined conditions

Less expensive
Gentle […]

CEO Today Magazine Awards – Winners

3rd December 2018
Aptamer Group is proud to receive the CEO Today Magazine United Kingdom Awards for distinguished performance by our CEO and Founder Arron Tolley.

The award recognises, identifies and honours the most respected companies and their C-level executives operating within the United Kingdom today. Researchers at CEO Today determine the eligibility of the CEO/Executive based […]

The Microbiology Show 2018

10th October 2018
Our Chief Technical Officer, David Bunka, gave a talk  on how aptamers can be used in microbiology at The Microbiology Show in Derby.

The Microbiology Show brings together the technology, equipment, consultancy and services associated with the field of microbiology together in one event. There were a series of keynote presentations from thought leaders in […]

Aptamer Group October 2018

19th October 2018.
This month data on our new improved delivery standard, webinar with Pall ForteBio, and interesting applications in targeted treatment and environmental detection of small molecules.

Following on from a successful Series A investment and lots of new data ongoing for multiple applications in the commercial and academic space the Aptamer Group would like to […]